Get the Stockscreener App
128.54
0.38%
0.49
After Hours:
128.44
-0.10
-0.08%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $128.54, with a volume of 5.47M.
It is up +0.38% in the last 24 hours and up +1.33% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$128.05
Open:
$128.075
24h Volume:
5.47M
Relative Volume:
0.89
Market Cap:
$223.51B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
16.12
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
+1.89%
1M Performance:
+1.33%
6M Performance:
-2.10%
1Y Performance:
+8.97%
1-Day Range:
$127.02
$129.01
1-Week Range:
$122.09
$129.52
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
128.54 | 222.66B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.96 | 150.26B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
372.29 | 143.44B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
105.02 | 135.12B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
86.75 | 50.38B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Accused Of Miscalculating Workers' Overtime - Law360
Assessing Abbott Laboratories (ABT) Valuation Following Steady 2024 Gains and Analyst Growth Projections - simplywall.st
Is Abbott Laboratories Stock Underperforming the S&P 500? - Yahoo Finance
Abbott Laboratories (ABT) Valuation in Focus After Renewed Trading Momentum - Yahoo Finance
Top Abbott Exec Cashes In on Stock Sale! - TipRanks
Insider Sell: Eric Shroff Sells Shares of Abbott Laboratories (A - GuruFocus
Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble? - MedCity News
Abbott Laboratories SVP Shroff sells $203k in stock - Investing.com India
Abbott shares safety concerns with millions of CGM sensors—7 deaths reported - Cardiovascular Business
Abbott to replace glucose monitors after deaths possibly linked to false readings - Crain's Chicago Business
Abbott Laboratories Limited Appoints Brian William Jordan as A New Director, Effective November 25, 2025 - MarketScreener
Exact Sciences stock rating downgraded to Hold by TD Cowen following Abbott deal - Investing.com
Canaccord Genuity downgrades Exact Sciences stock to Hold after Abbott deal - Investing.com India
Abbott issues US device correction for some glucose monitors over faulty readings risk - WTAQ
Abbott's Exact Sciences Acquisition Signals Maturation of Single-Site Specialty Dx Space - 360Dx
Abbott Laboratories Issues Correction on 3 Million Glucose Sensors Over Possible Faulty Readings - NTD News
Abbott mum on malfunction behind Freestyle Libre 3 recall - BioWorld MedTech
Abbott issues correction for millions of glucose sensors - MedTech Dive
Key facts: Abbott Labs to acquire Exact Sciences for $23 billion; recalls FreeStyle Libre 3 sensors - TradingView
Abbott issues medical device correction for some glucose monitors in U.S. - MarketScreener
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Jefferies cuts Exact Sciences to 'hold' after Abbott acquisition - TradingView
Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Jefferies downgrades Exact Sciences stock to Hold after Abbott acquisition - Investing.com
Jim Cramer on Abbott: “I Think It’s a Terrific Time to Do Some Buying” - MSN
Jim Cramer on Abbott: "I Think It's a Terrific Time to Do Some Buying" - Finviz
Exact Sciences (EXAS) Shares Surge on Abbott Acquisition Deal - GuruFocus
Notable healthcare headlines for the week: Abbott, Medtronic, Merck and J&J in focus - MSN
Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer - MSN
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
Abbott acquires cancer diagnostic company Exact Sciences for $21B - HealthExec
William Blair Remains a Buy on Abbott Laboratories (ABT) - The Globe and Mail
ABTAbbott Laboratories Stock Price and Quote - Finviz
Abbott Laboratories Stock Price Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
Abbott Labs stock to acquire Exact Sciences for $21 billion By Investing.com - Investing.com Nigeria
Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle - Benzinga
Abbott Laboratories: Not Passing The Test After Buying Test Maker Exact Sciences (ABT) - Seeking Alpha
Abbott to acquire Exact Sciences in $21 billion deal, aiming to lead in fast-growing cancer diagnostics market - Medical Economics
Abbott’s $21B Exact Sciences buy reveals future strategy - MedTech Dive
Abbott Laboratories to acquire Exact Sciences for $23B in largest-ever diagnostics deal - The Business Journals
Abbott Laboratories Acquires Exact Sciences In $23 Billion Deal - Patch
Abbott Labs stock to acquire Exact Sciences for $21 billion - Investing.com India
Abbott Labs stock gains as UBS reiterates Buy rating on Exact Sciences deal - Investing.com India
Abbott Laboratories’ Strategic Acquisition of Exact Sciences: Enhancing Diagnostics Business and Long-term Growth Prospects - TipRanks
Top 2 Healthcare Stocks Every New Investor Should Know - The Motley Fool
Street View: Brokerages downgrade Exact Sciences following acquisition by Abbott - TradingView
Abbott’s colon-screening deal stinks financially - TradingView
Barclays Sticks to Its Buy Rating for Abbott Laboratories (ABT) - The Globe and Mail
Abbott Breaks into Lucrative Cancer Screening Market with $21 Billion Exact Sciences Purchase - The Daily Upside
Abbott's $21B splurge signals long-awaited dealmaking thaw in health tech - Crain's Chicago Business
Madison's Exact Sciences purchased by Abbott Laboratories, Ancient canoe is the region's oldest - WPR
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):